the effect of febuxostat on vascular endothelial function in subjects with hyperuricemia and ischemic heart disease

the effect of febuxostat on vascular endothelial function in subjects with hyperuricemia and ischemic heart disease - the effect of febuxostat on vascular endothelial function in subjects with hyperuricemia and ischemic heart disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012342

Enrollment

Registered

2013-11-19

Start date

2013-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperuricemia and ischemic heart disease

Interventions

Lifestyle adjustment febuxostat administration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: subjects must match all conditions below. 1.patients with serum uric acid level over 7.0mg/dl. 2.patients with ischemic heart disease. 3.patients older than 20 years old. 4.patients agreed with consent form.

Exclusion criteria

Exclusion criteria: 1.patients with a history of hypersensitivity to febuxostat. 2.patients with AST or ALT level over than the twice the facilitie standard value. 3.patients with severe renal dysfunction(eGFR under 15 mL/min./1.73m2 or hemodialysis patients). 4.patients received the uric acid descent medicine within two weeks before competent judgment. 5.patients within 1weeks from onset of acute myocardial infarction. 6.patients underwent CABG and after radial artery graft excision. 7. patients with malignant tumor or past history of malignant tumor (except patients with no recurrence or who didn't need specialized treatment for malignant tumor within 5 recent years). 8.patients who take mercaptopurine hydrate ,azathioprine,pyrazinamide or ethambutol. 9.patients participated to other clinical trials within recent 6 months. 10.patients judged not to be suitable as a subject by attending doctor. Especially, patients with serum uric acid level over 9mg/dl should be considered about not to participate to this trial.

Design outcomes

Primary

Measure	Time frame
The amount of change of the RH-PAT index	—

Secondary

Measure	Time frame
1.the amount of change of serum uric acid value 2.achievement quotient of serum uric acid level under 6.0mg/dl 3.the amount of change of eGFR 4.the amount of change of BNP level 5.the amount of change of the level of maker of inflammation 6.the amount of change of the level of maker of oxidative stress 7.cadiac function indexes on echocardiography 8.change in exercise capacity indexes 9.simptom of angina pectoris 10.the amount of change of fasting blood glucose level and HbA1c	—

Measure

Time frame

1.the amount of change of serum uric acid value 2.achievement quotient of serum uric acid level under 6.0mg/dl 3.the amount of change of eGFR 4.the amount of change of BNP level 5.the amount of change of the level of maker of inflammation 6.the amount of change of the level of maker of oxidative stress 7.cadiac function indexes on echocardiography 8.change in exercise capacity indexes 9.simptom of angina pectoris 10.the amount of change of fasting blood glucose level and HbA1c

—

Countries

Japan

Contacts

Public ContactReiko Fujiwara

National Cerebral and Cardiovascular Center. Division of Cardiology

reikofuj@hsp.ncvc.go.jp06-6833-5012

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026